BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
May 8, 2025 • 20min
As the field builds on the initial success of PARP inhibitors, Artios Pharma is working on the next generation of DNA Damage Response (DDR)-based therapies - it just had clinical data on one at AACR
CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last week for its ATR kinase inhibitor. As he describes, patient selection for these therapies can make a big difference.
May 8, 2025 • 21min
Munich based ITM Radiopharma is progressing towards a first NDA in the U.S. with a robust pipeline behind it - all the while making investments in isotope manufacturing that has slowed others
CEO Andrew Cavey describes how ITM has been investing to avoid the shortages others have experienced, and explains how the supply chain works for radiopharmaceuticals. He walks us through the science behind these medicines before highlighting ITM's pipeline.
May 7, 2025 • 16min
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.
May 6, 2025 • 8min
Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format
CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.
May 6, 2025 • 9min
Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma
Pierluigi Paracchi, Co-Founder and CEO of Genenta Science, shares insights on the company's groundbreaking cell therapy approach for renal cell carcinoma. He explains the recent €20 million funding from ENEA Tech and Biomedical, highlighting the innovative convertible bond structure. Paracchi updates listeners on clinical trials and the exciting prospects for patient dosing, emphasizing the challenges and opportunities within the European biotech landscape. The conversation also touches on the impact of this investment on Genenta's future and advancements in the broader field of cancer therapy.
May 6, 2025 • 10min
Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
Emmanuel Savioz, Chairman & CEO of Tigen Pharma, dives into the revolutionary world of decentralized CAR-T manufacturing. He outlines how producing therapies closer to treatment sites enhances patient care. The discussion includes a cutting-edge armored-CAR program with Memorial Sloan Kettering, showcasing Tigen's innovative non-viral platform for combating blood cancers like NHL and multiple myeloma. Savioz emphasizes automation and AI's role in streamlining production, positioning Tigen at the forefront of an evolving pharmaceutical landscape.
May 6, 2025 • 10min
Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria
CEO Klaus Dugi describes why the company is focused on mitochondria and how it using small molecules to fix them. He covers the three main disease areas Vandria is focused on, including a clinical program in mild cognitive impairment.
May 6, 2025 • 11min
Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance
Co-Founder & CEO Marc Gitzinger describes the success factors behind the IPO and walks us through the company's two lead programs. Plus, his thoughts on the evolving business model for this field.
May 5, 2025 • 8min
Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens
CEO Franz-Werner Haas describes the rationale for developing vaccines for the antimicrobial space, he explains the company's E. coli based platform, and he walks us through the pipeline.
May 5, 2025 • 9min
Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers
CEO Marina Udier describes the vaccine's design, what was presented at AACR, and discussions the company has had with U.S. FDA about running a registrational study. Plus, previewing upcoming data later this year in metastatic colorectal cancer.
